Ctc Counts As A Biomarker Of Prognosis And Response In Metastatic Castration-Resistant Prostate Cancer (Mcrpc) From The Card Trial.

Johann S. De Bono,Klaus Pantel,Eleni Efstathiou,Cora N. Sternberg,Daniel Castellano,Karim Fizazi,Bertrand Tombal,Christian Wulfing,Joseph D. Schonhoft,Audrey Gill,Lincy Chu,Rick Wenstrup,Ayse Ozatilgan,Christine Geffriaud-Ricouard,Sandrine Macé,Ronald De Wit

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 2|浏览12

暂无评分

摘要

161Background: In the prospective CARD trial (NCT02485691), cabazitaxel significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) versus abiraterone or enzaluta...

查看译文

关键词

Cabazitaxel,Prostate cancer,Biomarker (medicine),Oncology,Medicine,Abiraterone,Castration resistant,Internal medicine,Overall survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要